THIS CONTRACT OF EMPLOYMENT dated 29 July 2015 is madeMereo Biopharma Group PLC • December 1st, 2017 • Pharmaceutical preparations • England
This Contract sets out the terms and conditions of your employment with the Company at the date of this Contract and supersedes all previous arrangements or agreements whether oral or in writing between you and the Company in relation to the matters dealt with in it.
Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. SUBLICENSE AGREEMENTSublicense Agreement • December 1st, 2017 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This SUBLICENSE AGREEMENT (this “Agreement”), effective as of July 29, 2015 (the “Effective Date”), is by and between MEREO BIOPHARMA 3 LIMITED, a private limited company incorporated in England and Wales (“Buyer”) and a wholly owned subsidiary of MEREO BIOPHARMA GROUP LIMITED, a company incorporated in England and Wales (“Mereo”), and NOVARTIS PHARMA AG, a Swiss company (“Novartis”).
EXCLUSIVE LICENSE AND OPTION AGREEMENTExclusive License and Option Agreement • December 1st, 2017 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This EXCLUSIVE LICENSE AND OPTION AGREEMENT (the “Agreement”) is made and entered into effective as of 28 October 2017 (the “Effective Date”) by and between ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482 with its registered office at SE-151 85 Sodertalje, Sweden (“AstraZeneca”), and MEREO BIOPHARMA 4 LIMITED, a company incorporated in England and Wales under no. 11029583 with its registered office at 4th Floor, One, Cavendish Place, London, W1G 0QF (“Mereo”). AstraZeneca and Mereo are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. BCT197 ASSET PURCHASE AGREEMENT by and between...Bct197 Asset Purchase Agreement • December 1st, 2017 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This BCT197 ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 28, 2015, by and between Novartis Pharma AG, a Swiss company (“Novartis”), and Mereo BioPharma 1 Limited, a private limited company incorporated in England and Wales (“Buyer”) and a wholly owned subsidiary of Mereo BioPharma Group Limited, a company incorporated in England and Wales (“Mereo”). Hereinafter, “Parties” shall mean Novartis and Buyer together, and “Party” shall mean either Novartis or Buyer, as the context requires.
Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. BGS649 ASSET PURCHASE AGREEMENT by and between...Bgs649 Asset Purchase Agreement • December 1st, 2017 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This BGS649 ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 28, 2015, by and between Novartis Pharma AG, a Swiss company (“Novartis”), and Mereo BioPharma 2 Limited, a private limited company incorporated in England and Wales (“Buyer”) and a wholly owned subsidiary of Mereo BioPharma Group Limited, a company incorporated in England and Wales (“Mereo”). Hereinafter, “Parties” shall mean Novartis and Buyer together, and “Party” shall mean either Novartis or Buyer, as the context requires.
MEREO BIOPHARMA GROUP PLC AND JOHN RICHARD AND JOHN RICHARD & ASSOCIATES, LLC CONSULTANCY AGREEMENTConsultancy Agreement • December 1st, 2017 • Mereo Biopharma Group PLC • Pharmaceutical preparations
This consultancy agreement (this “Agreement”) has been entered into this 1st day of Feb. 2017 and shall replace the agreement between the Parties dated 21 April 2016.
Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. BPS804 ASSET PURCHASE AGREEMENT by and between...Bps804 Asset Purchase Agreement • December 1st, 2017 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This BPS804 ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 28, 2015, by and between Novartis Pharma AG, a Swiss company (“Novartis”), and Mereo BioPharma 3 Limited, a private limited company incorporated in England and Wales (“Buyer”) and a wholly owned subsidiary of Mereo BioPharma Group Limited, a company incorporated in England and Wales (“Mereo”). Hereinafter, “Parties” shall mean Novartis and Buyer together, and “Party” shall mean either Novartis or Buyer, as the context requires.
